Precision BioSciences Inc. 8-K Summary
Business Context and Reporting Period
This Current Report on Form 8-K was filed by Precision BioSciences, Inc. (DTIL) on October 24, 2023. The report addresses a change in the listing status of the Company's common stock on The Nasdaq Stock Market.
Key Financial Metrics
The filing does not provide specific financial data such as revenue, profit, cash flow, margins, debt, or liquidity. The document focuses exclusively on regulatory compliance regarding stock listing standards.
Material Changes
- Listing Transfer: Nasdaq approved the transfer of the Company's common stock from the Nasdaq Global Select Market to the Nasdaq Capital Market, effective October 26, 2023.
- Reason for Transfer: The Company was previously notified on April 24, 2023, of non-compliance with Nasdaq Listing Rule 5450(a)(1) due to the closing bid price remaining below $1.00 for 30 consecutive business days.
- Compliance Period: The transfer grants an 180-day grace period until April 22, 2024, to regain compliance with the Minimum Bid Price Requirement.
Outlook, Risks, and Management Commentary
To maintain listing on the Nasdaq Capital Market, the Company must achieve a minimum bid price of at least $1.00 for at least ten consecutive business days within the 180-day compliance period. Failure to do so may result in delisting, though the Company retains the right to appeal to a Nasdaq Hearings Panel.
Management has notified Nasdaq of its intention to cure the deficiency by effecting a reverse stock split if necessary. The Company intends to actively monitor the bid price and consider available options to resolve deficiencies.
Investor Verification Checklist
- Verify the current trading status and symbol (DTIL) on the Nasdaq Capital Market.
- Monitor the daily closing bid price to track progress toward the $1.00 threshold.
- Review future filings for announcements regarding a potential reverse stock split.
- Check the April 22, 2024 deadline for compliance with the Minimum Bid Price Requirement.